Managing Clinical Expectations in Infections Due to Gram-Positive Bacteria
This activity was supported through an educational grant from AbbVie.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing medical education activity is provided by American Academy of CME, Inc.
Support Statement
This activity was supported through an educational grant from AbbVie.
Activity Description
The number of formally ID-trained pharmacists and physicians are limited across the country. This means that there is a growing role for general pharmacists and non-ID physicians to optimally manage their patients’ antibiotics in the hospital or outpatient setting as well as fulfill necessary expert roles in antibiotic stewardship programs. In order to do so, physicians and pharmacists will need education regarding the current state of drug-resistant infections and current/emerging antibiotic therapies. Physicians and pharmacists will need to understand the nuances of new antibiotics for treatment of MDR GPB and their role on the hospital formulary. Along with enhanced knowledge of this complex area of infectious diseases management, the ability to effectively communicate this knowledge and educate others on the healthcare team should be fostered and fulfilled. These e-monograph was designed to address these needs.
Target Audience
The intended audience for this activity is infectious disease physicians and pharmacists.
Learning Objectives
Upon completion of this activity, learners should be better able to:
1. Recall the epidemiology and mechanisms of drug-resistance among Gram-positive bacterial (GPB) infections
2. Analyze the pharmacology and antibacterial activity of current and emerging antibiotic therapies for multi-drug resistant (MDR) GPB infections including MRSA and VRE.
3. Explain the evidence and utility of new antibiotic therapies for MDR GPB infections.
4. Evaluate the role of the physician and pharmacist in managing antibiotic therapies for MDR GPB infections and their role as antibiotic stewardship program members
Faculty
Luis Manrique, MD
Infectious Disease Specialist
Infection Prevention/ASP Medical Director
Northwestern Medicine RMG
Radhika S. Polisetty, PharmD, BCIDP, BCPS, AAHIVP
Clinical Specialist, Infectious Diseases
Northwestern Medicine Central DuPage Hospital Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Reviewer
Pinki J. Bhatt, MD
Assistant Professor, Division of Infectious Diseases, Rutgers Robert Wood Johnson Medical School
Associate Program Director, Infectious Disease Fellowship
Adjunct Assistant Professor, Rutgers Ernest Mario School of Pharmacy
Accreditation
In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Academy is also accredited by the Commission on Dietetic Registration, and is a Provider approved by the California Board of Registered Nursing.
Credit Designation
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity provides 1.5 ACPE contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-22-034-H04-P, Application
How to Participate in This Activity and Obtain CE Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
1. Read the CME/CE information and faculty disclosures.
2. Participate in the online activity.
3. Complete the activity assessment (scoring at least 70%) and submit the evaluation form.
Pharmacists will receive their statement of credit through the NABP’s CPE Monitor in approximately 6-8 weeks. Only pharmacy learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit. All other participants will receive their certificate of credit via email.
Disclosures
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures are as follows:
Faculty Educators
|
Luis Manrique, MD |
no relevant financial relationships with ineligible organizations |
|
Radhika S. Polisetty, PharmD, BCIDP, BCPS, AAHIVP |
no relevant financial relationships with ineligible organizations |
Planning Committee
John JD Juchniewicz, MCIS, CHCP, FACEHP, Wendy Gloffke, PhD and Paul Miniter, MS - No relevant financial relationships with ineligible organizations.
External Reviewer
Pinki J. Bhatt, MDAssistant Professor, Division of Infectious Diseases
Rutgers Robert Wood Johnson Medical School
Associate Program Director, Infectious Disease Fellowship
Adjunct Assistant Professor, Rutgers Ernest Mario School of Pharmacy
Dr. Bhatt discloses no relevant financial relationships with ineligible organizations.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Off-label Disclosure
Daptomycin is FDA-approved to treat serious life-threatening infections such as bloodstream infections, endocarditis (prosthetic and native-valve), and complicated skin and skin-structure infections caused by MRSA, VRE, and methicillin-resistant S epidermidis. Daptomycin also is used off-label to treat meningitis, diabetic foot infections, cerebrospinal fluid shunt infections, and osteomyelitis, but is not FDA-approved for these indications.
Ceftaroline is FDA-approved to treat complicated skin and skin-structure infections and CAP. Ceftaroline has been used off-label to treat bloodstream infections and hospital-acquired pneumonia caused by MRSA but is not FDA-approved for these indications.
Ceftobiprole, iclaprim and teicoplanin are not available in the US.
Disclaimer
This activity is designed for educational purposes. The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm
Conteact Information
For CME questions please contact: ceservices@academycme.org.